Summary of AnaptysBio FY Conference Call (December 03, 2025) Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Industry**: Biopharmaceuticals Key Points Business Segments and Developments - **Biopharma Operations**: - **ANB033**: A CD122 antagonist, initiated a trial for celiac disease in 2025, with data expected in Q4 2026. A second trial for eosinophilic esophagitis (EOE) is planned for 2026 [4][19]. - **Rosnilimab**: Advanced program for rheumatoid arthritis (RA) with positive phase 2b data from a study involving 424 patients. Plans to move into phase 3 development in 2026 with external funding [4][12]. - **Royalty Management**: - **Jemperli**: Expected to generate $1.4 billion in sales at GSK, with significant royalty rights. The company plans to separate the royalty management business from biopharma assets in 2026 [5][31]. Clinical Trials and Efficacy - **Rosnilimab**: - Phase 2 trial in ulcerative colitis (UC) showed good safety but insufficient efficacy to continue. The focus will be on RA with a phase 3 design that includes placebo-controlled trials [6][8]. - 69% of patients achieved low disease activity (CDAI) by week 14, with a placebo-adjusted delta over 20% [11]. - Safety profile was unremarkable, with no malignancies or serious infections reported [15]. - **ANB033**: - Targeting celiac disease with a focus on mucosal healing, measuring villus height to crypt depth ratio. The phase 1B trial will assess both gluten challenge and patients with severe mucosal injury [20][22]. - The market for celiac disease treatment is estimated to be multi-billion dollars, with over 250,000 patients in the U.S. not well controlled on a gluten-free diet [26]. Financial and Strategic Considerations - The company anticipates ending 2025 with $300 million in cash, including $75 million milestone from GSK upon Jemperli exceeding $1 billion in sales [36]. - Plans to separate the biopharma and royalty management businesses in 2026, ensuring each can operate independently and maintain value [29][35]. - The royalty management business is projected to become cash flow positive by Q2 2027 [31][37]. Legal and Regulatory Issues - Ongoing litigation with GSK regarding Jemperli, with AnaptysBio contending that GSK is in breach of obligations related to the asset's development [33][34]. - The separation plans are independent of the litigation, ensuring that the biopharma operations can execute their strategy regardless of the trial outcome [35]. Market Outlook - The biopharma segment is expected to capture significant value post-separation, with potential for growth in both ANB033 and Rosnilimab [40]. - The company believes there is substantial upside in the biopharma business that is currently undervalued by the market [40]. Additional Insights - The company is exploring strategic partnerships for RA development while protecting its royalty stream [9][16]. - There is a focus on broadening the ANB033 program with potential for multiple indications, including EOE [39]. This summary encapsulates the critical developments and strategic outlook for AnaptysBio as discussed in the conference call, highlighting both opportunities and challenges within the biopharmaceutical landscape.

AnaptysBio (NasdaqGS:ANAB) FY Conference December 02, 2025 01:30 PM ET Company ParticipantsDaniel Faga - President and CEOConference Call ParticipantsYas Rahimi - Senior Biotech AnalystYas RahimiGood afternoon, everyone. Welcome to our Piper Sandler Healthcare Conference. My name is Yas Rahimi. I'm a Senior Biotech Analyst here at Piper Sandler, and the covering analyst of AnaptysBio. Dan, it's wonderful to have you. We have lots to cover over the next 25 minutes, and you have a packed schedule, so you've b ...

Group 1 - AnaptysBio, Inc. is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [2] - The company's pipeline includes rosnilimab, ANB033, and ANB101, with various stages of clinical trials [2] - Anaptys plans to separate its biopharma operations from its royalty assets by year-end 2026 to better align with investor interests [3] Group 2 - Upcoming investor conferences include the Piper Sandler 37th Annual Healthcare Conference and the Evercore 8th Annual Healthcare Conference [1] - Live webcasts of the events will be available on the Anaptys investor website, with replays accessible for at least 30 days [1] - The company is engaging in fireside chats and one-on-one investor meetings on specific dates in December 2025 [4]

Group 1 - ANAB stock increased by 4.7% in early trading [1] - Hims & Hers saw a rise of 4.3% [1] - Biogen (BIIB) shares rose by 2.7% [1] Group 2 - Eli Lilly experienced a slight decline [1] - Abbott's stock fell by over 0.6% [1] - Novo Nordisk ADR dropped by over 9% [1]

Group 1 - Google A shares increased by 2.3% following the release of its new AI image generation model, Nano Banana Pro [1] - Elastic's shares fell by 12.6% as its Q2 financial report indicated a slowdown in cloud business growth [1] - AnaptysBio's shares dropped by 11.1% due to a lawsuit filed against it by Tesaro, a subsidiary of GlaxoSmithKline [1] Group 2 - Bilibili's shares rose by 1.2% as institutional investors continued to express positive outlooks following its earnings report [1]

Core Viewpoint - AnaptysBio's shares dropped 14% in premarket trading following lawsuits filed against each other by AnaptysBio and Tesaro, a subsidiary of GSK, both alleging breach of contract [1] Company Summary - AnaptysBio is a U.S. drug developer that is currently involved in legal disputes with Tesaro [1] - The lawsuits indicate significant tensions between the two companies, potentially impacting their business relationships and future collaborations [1] Industry Summary - The legal actions reflect broader issues within the pharmaceutical industry regarding contract disputes and partnerships, which can lead to volatility in stock prices [1]

Core Viewpoint - GSK's subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, claiming a material breach of their existing license agreement regarding the oncology treatment Jemperli (dostarlimab) [1][2][3] Group 1: Litigation Details - The litigation allows Tesaro to terminate the current license agreement, obtain a perpetual and irrevocable license to dostarlimab, and reduce royalties and milestone payments to AnaptysBio by 50% [3] - AnaptysBio has alleged that Tesaro has not fulfilled certain requirements of the license agreement from March 2014 and intends to revoke Tesaro's license for dostarlimab [4][5] - The original agreement included an upfront license fee of $17 million and milestone payments of $18 million per development program, with additional payments tied to regulatory submissions [5] Group 2: Financial Implications - AnaptysBio anticipates ending 2025 with approximately $300 million in cash and investments, including a potential $75 million milestone from GSK once Jemperli achieves $1 billion in worldwide net sales [8] - AnaptysBio has authorized a stock repurchase plan of up to $100 million [7] Group 3: Product and Market Context - Jemperli is approved in over 35 countries for certain endometrial cancers, which is the most common gynecologic cancer in the U.S. [6] - A clinical trial program is ongoing to evaluate dostarlimab's potential use in additional cancers, including rectal, colon, and head and neck cancers [6]

Group 1: Elastic NV Performance - Elastic NV reported second-quarter adjusted earnings of 64 cents per share, exceeding the analyst estimate of 58 cents [1] - The company's quarterly revenue was $423.48 million, surpassing the Street estimate of $418.16 million [1] - Despite the positive earnings and revenue results, Elastic shares fell 12.3% to $72.02 in pre-market trading [1] Group 2: Other Stocks in Pre-Market Trading - Luda Technology Group Ltd experienced an 11.1% decline to $8.55 after a 39% gain on Thursday [4] - AnaptysBio Inc fell 9.7% to $34.00 following the announcement of a $100 million stock repurchase plan [4] - Sigma Lithium Corp dropped 8.4% to $8.61 after a 9% decline on Thursday [4] - Veeva Systems Inc decreased by 6.7% to $252.40 despite posting upbeat third-quarter results and raising fiscal year earnings and revenue estimates [4] - American Bitcoin Corp declined 6.3% to $4.29 in pre-market trading [4] - Standard Lithium Ltd fell 6.3% to $3.60 [4] - Indivior PLC declined 5.9% to $29.90 after settling a matter with the U.S. Department of Justice for $295 million [4] - HIVE Digital Technologies Ltd fell 5.8% to $2.75 after filing for mixed shelf [4] - Albemarle Corp decreased by 5.5% to $109.99 [4] - Oncology Institute Inc fell 2.1% to $3.17 [4]

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from a previous plan [1][2]. Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1]. - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1]. - The repurchase may occur through open market transactions or other means, with the plan set to expire on March 31, 2026, and can be suspended or discontinued at any time [3]. Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2]. Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4]. - The company has out-licensed therapeutic antibodies, including a PD-1 antagonist to GSK and an IL-36R antagonist to Vanda Pharmaceuticals [4]. - AnaptysBio plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5].

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from the previous plan [1][2] Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1] - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1] - The new plan will expire on March 31, 2026, and the timing and number of shares repurchased will depend on market conditions and other factors [3] Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2] Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4] - The company plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5]